Preeti Parikh

LifeScience consultant.

[Muthu Vaduganathan @mvaduganathan]

#CONFIDENCE 1⃣ + 1⃣ = 2⃣

Remarkably, kidney protection with combination therapy mathematically identical to what would be expected based on each monotherapy

Finerenone (0.68) * Empagliflozin (0.71)

Combination (Expected if Fully Additive): 0.48

Combination (Observed): 0.48

[Steve Greene @SJGreene_md]

Further evidence for simultaneous initiation of #GDMTworks in #CKM.

Incremental, fully additive, early benefits

Status quo, slow, serial, sequential approach =
⬆️ exposure to excess clinical risk
⬆️ chance patient never gets prescribed the therapy at all

@gcfmd @DCRINews

[Preeti Parikh @PreetiParikh]

@HomeCenter14 I have been trying to reach your customer service for a return a table since weeks! Pathetic service! Can someone please call me to resolve my issue ASAP

[Preeti Parikh @PreetiParikh]

@aramexofficiel can someone please call me urgently! Very unhappy with your service

[Ahmed Bennis MD 🫀 @drbennisahmed]

European Society of Cardiology quality indicators update for the care and outcomes of adults with heart failure. The HFA of the ESC

update of the previously published ESC QIs for HD to ensure that these measures aligned with contemporary evidence

https://t.co/TPrSw3nZmB

[Preeti Parikh @PreetiParikh]

@AppleSupport

[gaurav monga @mysteriousGM]

@Apple @AppleIndia #BoycottAppleProducts Shameful act and customer care in India, #Apple #scams I have been victim of #Apple Store code card scam, #Apple is encouraging such scams, refusing to address, customer care is utterly arrogant and continously misguiding me.

[Muthu Vaduganathan @mvaduganathan]

🔥🔥 #ESCCongress #LBCT Hot Lines Released

#FINEARTSHF nsMRA finerenone in HFmrEF/pEF @scottdsolomon

#MRAs in HF: #FINEARTSHF & 3 sMRA HF RCTs @PSJhund

#FINEHEART finerenone across #CKM: #FINEARTSHF & 2 CKD RCTs

Can't wait to see you on the world's biggest scientific stage!

[Duke Clinical Research Institute @DCRINews]

Decongestion is a key part of HF inpatient management, yet a new study in @JACCJournals featuring @SJ_Greene and @FudimMarat found many patients are discharged weighing the same or more than when admitted. Read their full findings here: https://t.co/B6RUe77wPt

[Prof Kamlesh Khunti @kamleshkhunti]

Timing of Cardio-Kidney Protection With SGLT2 Inhibitor varies in trials

Herat failure benefits occur early
MACE events evident early
Cardiovascular deaths & kidney outcome benefits much later

https://t.co/fKkkv9ioSl

@brendonneuen @mvaduganathan et al

[Peter Rossing @P_Rossing]

See the long-term (lifetime) effects of dapagliflozin in chronic kidney disease: a time-to-event analysis https://t.co/KB1IAkebwp @Stenodiabetes @NDTsocial

[The Lancet @TheLancet]

Semaglutide—a new treatment for obesity-related heart failure with preserved ejection fraction?

1️⃣ Pooled analysis of the placebo-controlled STEP-HFpEF and STEP-HFpEF DM trials: https://t.co/X4COYs6TxM
2️⃣ Linked Comment: https://t.co/gBetzV0Eik

[ACC Media Center @ACCmediacenter]

The EMPACT-MI study presented by @javedbutler1 at #ACC24 found that use of the #SGLT2 empagliflozin did not reduce mortality after a #HeartAttack but did reduce the risk of #HeartFailure after heart attack. #CardioX https://t.co/5LCJIaEkBO @bswhealth

[Muthu Vaduganathan @mvaduganathan]

Combination Rx is now standard of care across #CKM

#CKD (+T2D) @CircAHA
RASi+SGLT2i+nsMRA+GLP1RA
https://t.co/xQoaQHybZ0

#HFrEF @JACCJournals #JACCHF
ARNI+BB+MRA+SGLT2i
https://t.co/5AkPxdEUba

#HFmrEF/#HFpEF @JACCJournals #JACCHF
ARNI+MRA+SGLT2i(+/-BB)
https://t.co/jLnqB8HrrY

[Gregg Fonarow MD @gcfmd]

🎛️ Quadruple rather than double

⏱️ Fast rather than slow

✅ Systematic rather than haphazard

Eligibility and Projected Benefits of Rapid Initiation of Quadruple Medical Therapy

https://t.co/eY4tvTYPSn.…
@AHAScience #cardiology #CardioTwitter #CVD #CardioEd @JACCJournals

[RAS Life Science Solutions @raslss]

6th epi of #KnowYourTrial series! Explore the latest assets in #clinicaldevelopment, therapy areas, and #drug classes. Our KYT series highlights pros transitioning from molecule discovery to human #clinicaltrials in Sep 2023. Stay tuned for #pharmaceuticalindustry insights!

[RAS Life Science Solutions @raslss]

Will ADCs integrate into or replace the current standard of care in metastatic diseases?
The insights to this and many more came from the AZ and DS sponsored ESMO coloquim at ESMO 2023 conference in Madrid Spain #esmo2023 #raslss #oncology

[RAS Life Science Solutions @raslss]

We are attending #PARISNASH, follow for more updates
https://t.co/c19SbuJTXx
#NASH #NAFLD #liver #steatosis #inflammation #ballooning #fibrosis #PARISNASH

[European Society of Cardiology @escardio]

Early initiation of the sodium glucose co-transporter 2 (#SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in hospitalised patients with acute decompensated heart failure (ADHF).

#ESCCongress DICTATE-AHF trial - Early dapagliflozin initiation in acute heart failure.

[RAS Life Science Solutions @raslss]

Some hard evidence of the utility of #wearables was presented by Prof. Svennberg in her #digitalhealth talk at ⁦#esc2023. The studies are small but the meta-analysis gives us a positive indicator that the #wearables do encourage physical activity.

[RAS Life Science Solutions @raslss]

However, gaps still exist. Inga Drossart at #esc2023 presented a complex yet comprehensive picture of the #digitaldivide that still exists with #design and #interoperability as two major issues (among others) that adversely affect the uptake of devices in healthcare